p53 Mutation and MDM2 amplification are rare even in human papillomavirus‐negative cervical carcinomas

Cancer

Volumn 76, Issue 1, 1995, Pages 57-66

  Ikenberg, Hans ^a   Matthay, Klaus ^a   Schmitt, Beate ^a   Bauknecht, Thomas ^a   Kiechle‐Schwarz, Marion ^a   Göppinger, Axel ^a   Pfleiderer, Albrecht ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

cervical carcinoma; human papilloma virus; MDM2; p53; SSCP

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEQUENCE ANALYSIS; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; WART VIRUS;

ADULT; CERVIX NEOPLASMS; DNA, NEOPLASM; EXONS; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMAN; MIDDLE AGE; PAPILLOMAVIRUS, HUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; SUPPORT, NON-U.S. GOV'T;

EID: 0029074268     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950701)76:1<57::AID-CNCR2820760108>3.0.CO;2-4     Document Type: Article

References (59)

1. P53 mutations in human cancers
2. Clinical implications of the p53 tumorsuppressor gene
3. P53 function and dysfunction
4. Specific repression of TATA‐mediated but not initiator‐mediated transcription by wild‐type p53
5. A mammalian cell cycle check point pathway utilizing p53 and GADD45 is defective in ataxia‐teleangiectasia
6. Thymocyte apoptosis induced by p53‐dependent and independent pathways
7. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens
8. Gain of function mutations in p53
9. Association of human papillomavirus types 16 and 18 E6 proteins with p53
10. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
11. P53 point mutations in HPV‐negative human cervical carcinoma cell lines
12. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
13. Analysis of the p53 gene in human uterine carcinoma cell lines
14. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines
15. Clonal p53 mutation in primary cervical cancer: association with human‐papillomavirus‐negative tumours
16. Papillomaviruses, p53, and cervical cancer
17. Papillomaviruses, p53, and cervical cancer
18. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection
19. Loss of heterozygosity on chromosome 17p and mutant p53 in HPV‐negative cervical carcinomas
20. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes
21. The state of p53 in primary human cervical carcinomas and its effect in human papillomavirus‐immortalized human cervical cells
22. Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas
23. P53 mutation and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix
24. Mutations of p53 and human papillomavirus infection in cervical carcinoma
25. P53 mutations in HPV‐negative cervical carcinoma
26. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
27. The mdm2‐oncogene product forms a complex with the p53 protein and inhibits p53‐mediated transactivation
28. The mdm2‐oncogene can overcome wild‐type p53 suppression of transformed cell growth
29. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm2, and mutant p53
30. Mdm2 expression is in duced by wild type p53 activity
31. The p53‐mdm2 autoregulatory feedback loop
32. Amplification of a gene encoding a p53‐associated protein in human sarcomas
33. MDM2 gene amplification in metastatic osteosarcoma
34. P53 mutation and MDM2 amplification in human soft tissue sarcomas
35. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutation
36. Announcement. FIGO stages—1988 revision
37. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions
38. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity
39. The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection
40. Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay
41. General primer‐mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas
42. Enzymatic amplification of β‐globin genomic sequences and restriction site analysis for diagnosis of siccle cell anemia
43. Detection of polymorphisms of human DNA by gel‐electrophoresis as single‐strand conformation polymorphisms
44. P53 mutations in ovarian cancer: a late event?
45. DNA sequencing with chainterminating inhibitors
46. Polymorphism at codon 213 within the p53 gene
47. Molecular pathogenesis of cancer of the cervix and its causation by specific HPV types
48. Status of c‐myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus
49. Polymorphism at codon 36 of the p53 gene
50. Modulation of activity of the promoter of the human MDR1 gene by ras and p53
51. A genetic model for colorectal tumorigenesis
52. Clonal expansion of p53 mutant cells is associated with brain tumor progression
53. P53: At the crossroads of molecular carcinogenesis and risk assessment
54. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas
55. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion
56. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells
57. The short arm of chromosome 11 is likely involved in the regulation of the human papillomavirus type 16 early enhancer‐promoter and in the suppression of the transforming activity of the viral DNA
58. Cervical carcinoma: low frequency of allele loss at loci implicated in other common malignancies
59. It was a very good year for DNA repair